Human Vaccines Project

Partnership objectives

The Human Vaccines Project offers an unprecedented opportunity to merge cutting-edge academic science with industry product development capabilities to elucidate how the human immune system confers effective immunity, and thus accelerate the development of new interventions to prevent a broad range of infectious diseases and cancers.

This will be achieved by:

  1. Deciphering the human immunome, the ‘parts list’ of the immune system, to give the scientific community tools aiming at developing the next generation of vaccine discovery;
  2. Establishing the ‘rules of immunogenicity’, the optimal immunisation strategies to help prevent and control major infectious and neoplastic diseases;
  3. Optimising ‘immunologic fitness’ in global populations including infants, the elderly and vulnerable people (immunocompromised), in view to speed up the development of new vaccines and cancer immunotherapies.

Together, these efforts aim to dramatically transform the nature of vaccine and immunotherapy development, and thus disease prevention and treatment.

The Project aims to accelerate the development of vaccines and immunotherapies against major global infectious diseases and cancers by decoding the human immune system. The Project aims to accelerate the development of vaccines and immunotherapies against major global infectious diseases and cancers by decoding the human immune system. Copyright IAVI

Description of partnership activities and how they address needs and challenges

The Human Vaccine Project is structured as a non-profit public-private partnership. 

The Project, incubated at the International AIDS Vaccine Initiative (IAVI), brings together leading academic research centers, nonprofits, governments and five research-based pharmaceutical partners: Regeneron, Sanofi Pasteur, GlaxoSmithKline, Pfizer, MedImmune, a member of AstraZeneca Group and Janssen Pharmaceutical Companies of Johnson & Johnson. Insights gained will guide the development of potentially improved vaccines against diseases such as influenza, dengue, HIV and other infectious illnesses as well as cancer.

Partnership information

Company(ies) AstraZeneca , GlaxoSmithKline , Johnson & Johnson , Pfizer , Sanofi

Partner(s) Aeras Global TB Vaccine Foundation, Gilead Sciences, International AIDS Vaccine Initiative, Regeneron, Robert Wood Johnson Foundation, Vanderbilt University

Type of Partner(s) Academia / Hospitals, NGOs, Other Business, PDPs

Therapeutic Focus Infectious Diseases, Non-Communicable Diseases, Vaccine-Preventable Diseases, Neglected Tropical Diseases

Disease(s) Cancer, Ebola, HIV/AIDS, Influenza, Malaria, Tuberculosis

Program Type(s) Prevention Programs - Vaccines, Research & Development - Development of Treatments

Targeted Population(s) General population

Region(s) World

Number of Countries 1

Country(ies) Worldwide

Start Date 2014

More information Press release

Anticipated completion date 2024

« It is a tremendously exciting time in vaccinology as we move toward preventing very challenging global killers such as AIDS, TB, malaria, Ebola, and cancers. Science and innovation will get us the vaccines we need »

Stanley Plotkin, Emeritus Professor of the University of Pennsylvania and Chairman of the Human Vaccines Project Steering Committee.